Form 4: Vistagen Director Granted 17,600 Stock Options

Vistagen Therapeutics Director Mary L. Rotunno was granted 17,600 non-qualified stock options with an exercise price of $3.61, vesting monthly over one year.

Summary

• Director Mary L. Rotunno of Vistagen Therapeutics, Inc. was granted 17,600 non-qualified stock options.
• The options have an exercise price of $3.61 per share.
• The grant was made on September 9, 2025, and the options expire on September 9, 2035.
• The options vest in twelve equal monthly installments, commencing on the grant date.
• This grant was made under the company's Amended and Restated 2019 Omnibus Equity Incentive Plan.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a routine compensation event, aligning director interests with shareholders, but does not indicate significant operational news.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value through equity participation.
• The vesting schedule encourages continued service and commitment from the director over the next year.

Negatives

• The exercise price of $3.61 indicates the stock needs to trade above this price for the options to be in-the-money, representing a potential dilution if exercised and the stock price increases significantly.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised and stock price rises, but also aligns director's interests with share price appreciation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director as part of their compensation package. While it aligns the director's interests with shareholder value, it does not provide new material information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation based solely on this filing.

Keywords

Vistagen Therapeutics, VTGN, Stock Options, Form 4, Insider Transaction, Equity Incentive Plan, Director Compensation